Harmony Biosciences/$HRMY
13:30
21:10
04:45
12:25
20:00
1D1W1MYTD1Y5YMAX
About Harmony Biosciences
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Ticker
$HRMY
Sector
Primary listing
Employees
293
Headquarters
Website
HRMY Metrics
BasicAdvanced
$1.6B
10.25
$2.71
0.84
-
Price and volume
Market cap
$1.6B
Beta
0.84
52-week high
$40.87
52-week low
$25.52
Average daily volume
1.1M
Financial strength
Current ratio
3.597
Quick ratio
3.459
Long term debt to equity
17.027
Total debt to equity
19.449
Interest coverage (TTM)
14.23%
Profitability
EBITDA (TTM)
233.804
Gross margin (TTM)
77.16%
Net profit margin (TTM)
18.27%
Operating margin (TTM)
24.00%
Effective tax rate (TTM)
26.21%
Revenue per employee (TTM)
$2,960,000
Management effectiveness
Return on assets (TTM)
11.48%
Return on equity (TTM)
20.75%
Valuation
Price to earnings (TTM)
10.255
Price to revenue (TTM)
1.84
Price to book
1.84
Price to tangible book (TTM)
2.05
Price to free cash flow (TTM)
5.094
Free cash flow yield (TTM)
19.63%
Free cash flow per share (TTM)
5.455
Growth
Revenue change (TTM)
21.51%
Earnings per share change (TTM)
7.97%
3-year revenue growth (CAGR)
25.64%
3-year earnings per share growth (CAGR)
-3.01%
What the Analysts think about HRMY
Analyst ratings (Buy, Hold, Sell) for Harmony Biosciences stock.
HRMY Financial Performance
Revenues and expenses
HRMY Earnings Performance
Company profitability
HRMY News
AllArticlesVideos
Harmony Biosciences to Participate in Upcoming Investor Conferences
Business Wire·1 week ago
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
Business Wire·2 weeks ago
Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Harmony Biosciences stock?
Harmony Biosciences (HRMY) has a market cap of $1.6B as of March 13, 2026.
What is the P/E ratio for Harmony Biosciences stock?
The price to earnings (P/E) ratio for Harmony Biosciences (HRMY) stock is 10.25 as of March 13, 2026.
Does Harmony Biosciences stock pay dividends?
No, Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders as of March 13, 2026.
When is the next Harmony Biosciences dividend payment date?
Harmony Biosciences (HRMY) stock does not pay dividends to its shareholders.
What is the beta indicator for Harmony Biosciences?
Harmony Biosciences (HRMY) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.